Study guide
4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes
Key Takeaways Explain This Topic AI
Betamethasone 12 mg intramuscularly every 24 hours for two doses, or dexamethasone 6 mg every 12 hours for four doses, is given for anticipated preterm birth from 24 0/7 through 33 6/7 weeks.
Magnesium sulfate for fetal neuroprotection is given from 24 0/7 to 31 6/7 weeks as a 4 g load followed by 1 g per hour, reducing cerebral palsy in survivors.
Indomethacin tocolysis is restricted to pregnancies under 32 0/7 weeks and to 48 hours because of ductus arteriosus constriction and oligohydramnios.
A negative fetal fibronectin below 50 ng/mL has better than 95 percent negative predictive value for birth within 7 to 14 days, but the swab must precede digital exam, transvaginal ultrasound, and intercourse within 24 hours.
Amoxicillin-clavulanate is contraindicated for PPROM latency therapy because it increases neonatal necrotizing enterocolitis; the regimen is ampicillin plus erythromycin or azithromycin, then oral amoxicillin plus erythromycin, with delivery planned at 34 0/7 weeks.
Last updated: September 2026
Preterm Labor: Assessment & Clinical Management Bundle
Preterm labor is defined as regular uterine contractions accompanied by cervical dilation and/or effacement occurring between 20 0/7 and 36 6/7 weeks gestation .
Clinical Evaluation & Diagnostic Biomarkers
Uterine Contractions: Regular, painful contractions (≥4 every 20 minutes or ≥8 in 60 minutes).
Cervical Examination: Documented progressive cervical change, or initial cervical dilation ≥2 cm and/or effacement ≥80%.
Transvaginal Ultrasound Cervical Length (TVUS CL): Highly sensitive screening tool. A cervical length >30 mm has a high negative predictive value (>95%) for delivery within 14 days, whereas a cervical length <20 mm strongly predicts impending preterm delivery.
Fetal Fibronectin (fFN): An extracellular matrix glycoprotein found at the decidual-chorionic interface. Disruption of the interface releases fFN into cervicovaginal secretions. Tested between 22 0/7 and 34 6/7 weeks:
Negative fFN (<50 ng/mL): High negative predictive value (>95% to 99% probability that delivery will not occur within the next 7 to 14 days), allowing safe de-escalation of interventions and avoidance of unnecessary hospitalizations.
Testing Precautions: Cervicovaginal specimens must be collected prior to digital examination, transvaginal ultrasound, or sexual intercourse within the preceding 24 hours, which yield false-positive results. Gross bleeding also invalidates the test.
The Evidence-Based Preterm Labor Care Bundle (24 0/7 to 33 6/7 Weeks)
When active preterm labor is diagnosed in pregnancies prior to 34 weeks, an immediate multimodal bundle of evidence-based pharmacotherapies is initiated: [ PRETERM LABOR CLINICAL BUNDLE: 24 0/7 – 33 6/7 WEEKS ]
- │
- ┌────────────────────┬───────────────────┴───────────────────┬────────────────────┐
- ▼ ▼ ▼ ▼
- [ Antenatal Steroids ] [ Short-Term Tocolysis ] [ Neuroprotection ] [ GBS Prophylaxis ]
- Betamethasone 12mg IM Oral Nifedipine or Magnesium Sulfate IV Penicillin G
- q24h x 2 doses Indomethacin (for ≤48h) 4g load, 1g/h 5 million units load,
- Reduces RDS, IVH, Allows steroid completion Reduces Cerebral then 2.5–3.0 MU q4h
- NEC, & mortality and maternal transport Palsy (<32 weeks) until delivery
- 1. Antenatal Corticosteroids
Indications: All pregnant individuals between 24 0/7 and 33 6/7 weeks gestation at risk of preterm delivery within 7 days. Also considered in the periviable period (22 0/7–23 6/7 weeks) and in late preterm gestations (34 0/7–36 6/7 weeks) if delivery is expected within 7 days and steroids were not administered previously.
Regimens:
Betamethasone: 12 mg IM administered every 24 hours for two doses (preferred), OR
Dexamethasone: 6 mg IM administered every 12 hours for four doses .
Mechanism & Benefits: Corticosteroids induce fetal pulmonary type II pneumocytes to synthesize and release surfactant. Administration dramatically reduces the incidence and severity of neonatal respiratory distress syndrome (RDS) , intraventricular hemorrhage (IVH) , necrotizing enterocolitis (NEC) , and neonatal mortality .
2. Short-Term Tocolytic Pharmacotherapy
Tocolytics are utilized strictly for short-term suppression of uterine contractions (up to 48 hours ) to permit the administration of antenatal corticosteroids and facilitate maternal transfer to a facility equipped with an appropriate-level neonatal intensive care unit. Tocolytics do not prolong pregnancy to term.
Nifedipine (First-Line Calcium Channel Blocker): Oral loading dose of 20 to 30 mg, followed by 10 to 20 mg orally every 4 to 6 hours for up to 48 hours. Well-tolerated; monitor for maternal hypotension, peripheral flushing, and headache.
Indomethacin (First-Line Prostaglandin Synthetase Inhibitor): Oral or rectal loading dose of 50 to 100 mg, followed by 25 to 50 mg orally every 6 hours for a maximum of 48 hours .
Strict Gestational Age Limitation: Reserved for pregnancies <32 0/7 weeks . Use beyond 32 weeks or for longer than 48 hours carries severe fetal risks: premature constriction of the ductus arteriosus (causing fetal pulmonary hypertension) and oligohydramnios (due to reduced fetal renal blood flow).
3. Magnesium Sulfate for Fetal Neuroprotection
Indication: Administered to individuals between 24 0/7 and 31 6/7 weeks gestation who are in active preterm labor with anticipated delivery within 12 to 24 hours.
Dosing: Intravenous loading dose of 4 grams over 20 to 30 minutes, followed by a continuous infusion of 1 gram/hour until delivery or for a maximum of 24 hours.
Benefit: Neuroprotection stabilizes neuronal membranes and microvascular cerebral blood flow, producing a substantial reduction in the incidence and severity of cerebral palsy and gross motor dysfunction in surviving preterm infants.
4. Group B Streptococcus (GBS) Chemoprophylaxis
Because GBS culture results are rarely available in preterm labor, empiric intravenous antibiotic prophylaxis is initiated upon admission:
First-Line: Intravenous Penicillin G (5 million units IV loading dose, followed by 2.5 to 3.0 million units IV every 4 hours until delivery).
Penicillin-Allergic: Cefazolin (mild allergy) or Clindamycin/Vancomycin (severe anaphylactic allergy, based on susceptibility testing).
Preterm Premature Rupture of Membranes (PPROM)
Preterm premature rupture of membranes is defined as rupture of fetal chorioamniotic membranes prior to 37 0/7 weeks gestation and before the onset of regular uterine contractions. It precedes one-third of all preterm births.
Confirmation of Membrane Rupture
Evaluation must be conducted via sterile speculum examination . Digital cervical examination is strictly contraindicated because digital exams introduce vaginal flora through the open cervical os into the amniotic cavity, markedly shortening the latency period and accelerating the development of intraamniotic infection.
Classic Diagnostic Triad:
Direct Pooling: Direct visualization of clear amniotic fluid pooling in the posterior vaginal fornix or egress of fluid from the external cervical os upon coughing or fundal pressure.
Nitrazine Paper Test: Amniotic fluid is alkaline (pH 7.0 to 7.3), turning yellow nitrazine paper deep blue (vaginal secretions are normally acidic, pH 3.8 to 4.5). False-positive results occur in the presence of semen, blood, cervical mucus, or bacterial vaginosis.
Microscopic Ferning Test: Air-dried fluid examined under low-power microscopy displays a distinctive arborization or ferning pattern driven by the crystallization of sodium chloride in the presence of amniotic proteins and estrogen.
Clinical Management Protocol (24 0/7 to 33 6/7 Weeks)
In the absence of infection or fetal distress, expectant inpatient management is maintained until 34 0/7 weeks to maximize fetal maturation:
Hospital Admission: Strict inpatient bed-to-chair rest and serial monitoring for intraamniotic infection (daily maternal temperature, maternal pulse, fetal heart rate, and uterine tenderness).
Antenatal Corticosteroids: Single course of betamethasone (12 mg IM q24h x 2 doses).
Latency Antibiotic Regimen (7-Day Course): Prolongs latency, reduces neonatal sepsis, and prevents chorioamnionitis:
Initial 48 Hours (IV): Intravenous Ampicillin (2 grams IV every 6 hours) PLUS intravenous Erythromycin (250 mg IV every 6 hours) or oral Azithromycin (1 gram PO single dose) .
Subsequent 5 Days (Oral): Oral Amoxicillin (250 mg PO every 8 hours) PLUS oral Erythromycin base (333 mg PO every 8 hours) .
Absolute Contraindication: Amoxicillin-clavulanic acid (Augmentin) is strictly contraindicated for latency therapy because it significantly increases the risk of neonatal necrotizing enterocolitis (NEC) .
Delivery Timing: Planned induction of labor is initiated at 34 0/7 weeks gestation . Immediate delivery is indicated regardless of gestational age if overt intraamniotic infection (chorioamnionitis), placental abruption, umbilical cord prolapse, or non-reassuring fetal status develops.